Search Results

Candel’s trial was conducted under the FDA’s Special Protocol Assessment program, meaning that its data could be used as a basis for a regulatory application.

Pixium Vision SA announces the completion of the reverse stock split, as decided by its Board of Directors on July 27, 2023 on the basis of 1 new share with a par value of 1 euro for 50 existing shares with a par value of 0.02 euro, as authorized at the Extraordinary Shareholders’ Meeting under the Second Resolution on March 8, 2023.

Tiziana Life Sciences Ltd. today announced a publication in the preeminent1 journal, Proceedings of the National Academy of Sciences (PNAS), that illustrates the immunological basis of the mechanism of action (MoA) for intranasal foralumab.

BioSig Technologies, Inc., a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares.

Evelo Biosciences, Inc. (Nasdaq:EVLO) today announced the publication of a peer-reviewed article explaining the scientific basis of the Small Intestinal Axis1 and that it will hold a Science Symposium on Wednesday, November 30th, including discussion of how this science enables the broad inflammation resolving potential of SINTAX medicines.

Elysium Health, Inc.™, a leading life sciences company focused on aging research, today announced that the detailed results from its clinical trial on Basis™ (NRPT) in people with non-alcoholic fatty liver disease (NAFLD) were published in Hepatology.

Rockwell Medical, Inc. announced financial and operational results for the three months and twelve months ended December 31, 2023.